Stocks · News reference
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last
Read original at benzingaEupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where all seven board nominees were elected with strong shareholder support. The company also re-appointed KPMG LLP as auditor. Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release products using its proprietary Diffusphere™ technology, with current programs in pain management and inflammatory gastrointestinal disease.
Read original at globenewswire-inc